Wednesday, 16 Jan 2019

You are here

Osteoarthritis and the Risk of Mortality

Osteoarthritis (OA) affects 27 million Americans but its affect on mortality is uncertain. A recent study shows that while self-reported OA does not increase mortality, radiographic OA of the knee (RKOA) is associated with higher mortality related to CVD, diabetes and renal disease.

An analysis of adults in the 1988–94 and 1999–2010 National Health and Nutrition Examination Survey (NHANES) data looked at age related, self-reported and radiographic knee OA (RKOA) defined as Kellgren–Lawrence score ≥2. 

Among a sample of 51938 participants, 2589 of them had knee X-rays, with a prevalence of 6.6%. By contrast self-reported OA was seen in 40.6%. The latter was not associated with mortality.

RKOA was associated with an increased risk of mortality from cardiovascular diseases (CVD) {HR 1.43 [95% confidence interval (CI): 1.32, 1.64]}, diabetes [HR 2.04 (1.87, 2.23)] and renal diseases [HR 1.14 (1.04, 1.25)].  Conversely RKOA was associated with a reduced risk of cancer mortality [HR 0.88 (0.80, 0.96)].

Those diagnosed with early RKOA onset (before age 40) had a higher risk of mortality from all causes [HR 1.53 (1.43, 1.65)] and from diabetes [HR 7.18 (5.45, 9.45)].

Obese participants with RKOA were at increased risk of mortality from CVD [HR 1.89 (1.56, 2.29)] and from diabetes [HR: 3.42 (3.01, 3.88)].


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Heberden’s Nodes Predict Knee OA Progression

Hand and knee osteoarthritis are considered to be clinically and pathogenically different and distinct, but a new study suggests that Heberden's nodes (HNs) can predict MRI‐based knee osteoarthritis (OA) progression.

An NIH study of 575 subjects included clinical examination with evaluation of HNs at baseline and knee MRI at baseline and 24‐month.

NEJM Review - Glucocorticoid-Induced Osteoporosis

Lenore Buckley and Mary Humphrey have published a nice review of glucocorticoid-induced osteoporosis (GIOP) in the NEJM.

Uncertain Long Term Efficacy in Trials of Knee Osteoarthritis

A systematic review and network meta-analysis of 47 randomized clinical trials in knee osteoarthritis finds uncertainty around estimates of effect size for pain scores thereby casting uncertainty over the long-term efficacy of medications for knee osteoarthritis.

Zolendronate Protects Against Fracture in Osteopenia

The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.

While it is known that bisphonates have beneficial effects in osteoporosis, their impact in osteopenia has not been shown. 

Dendrimer Nanocarrier Delivers IGF-1 to Degenerative Cartilage

Researchers from MIT have developed a novel treatment for osteoarthritis (OA) by using dendrimer-based nanocarriers to deliver insulin-like growth factor 1 (IGF-1) to chondrocytes within joint cartilage and in animal models have shown when these nanocarriers injected into rat knees in models of OA, they reduced cartilage degeneration.